| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|
MMWR Recomm Rep
|
2010
|
8.16
|
|
2
|
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.
|
MMWR Recomm Rep
|
2005
|
6.45
|
|
3
|
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
|
Lancet
|
2002
|
3.95
|
|
4
|
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
|
Am J Respir Crit Care Med
|
2009
|
3.57
|
|
5
|
The effects of local review on informed consent documents from a multicenter clinical trials consortium.
|
Control Clin Trials
|
2003
|
3.30
|
|
6
|
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
|
Am J Respir Crit Care Med
|
2006
|
3.20
|
|
7
|
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.
|
PLoS Med
|
2009
|
3.05
|
|
8
|
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
|
Am J Respir Crit Care Med
|
2003
|
2.56
|
|
9
|
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
|
Am J Respir Crit Care Med
|
2004
|
2.40
|
|
10
|
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
|
Clin Infect Dis
|
2005
|
2.34
|
|
11
|
Lack of weight gain and relapse risk in a large tuberculosis treatment trial.
|
Am J Respir Crit Care Med
|
2006
|
2.23
|
|
12
|
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.
|
PLoS Med
|
2009
|
1.95
|
|
13
|
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
|
Am J Respir Crit Care Med
|
2015
|
1.86
|
|
14
|
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
|
Am J Respir Crit Care Med
|
2005
|
1.85
|
|
15
|
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
|
J Infect Dis
|
2012
|
1.53
|
|
16
|
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
|
Antimicrob Agents Chemother
|
2010
|
1.45
|
|
17
|
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
|
Curr Opin Pulm Med
|
2010
|
1.27
|
|
18
|
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
|
Antimicrob Agents Chemother
|
2007
|
1.26
|
|
19
|
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
|
Am J Respir Crit Care Med
|
2002
|
1.23
|
|
20
|
Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis.
|
Emerg Infect Dis
|
2009
|
1.05
|
|
21
|
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
|
Am J Respir Crit Care Med
|
2010
|
1.01
|
|
22
|
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
|
Clin Infect Dis
|
2005
|
0.94
|
|
23
|
The association between symptoms and microbiologically defined response to tuberculosis treatment.
|
Ann Am Thorac Soc
|
2013
|
0.92
|
|
24
|
Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22).
|
Contemp Clin Trials
|
2006
|
0.89
|
|
25
|
Quality assurance in a large clinical trials consortium: the experience of the Tuberculosis Trials Consortium.
|
Contemp Clin Trials
|
2006
|
0.80
|
|
26
|
Advancing the science in clinical trials for new TB drugs.
|
Int J Tuberc Lung Dis
|
2008
|
0.78
|
|
27
|
A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
|
Am J Respir Crit Care Med
|
2015
|
0.77
|
|
28
|
Another step on the path to better TB therapies.
|
Int J Tuberc Lung Dis
|
2002
|
0.75
|
|
29
|
A trial involving HIV-tuberculosis in India: the minute particulars.
|
Am J Respir Crit Care Med
|
2010
|
0.75
|